Investors & Media
1 Feb. 2017

Kamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6

Link to webcast

NESS ZIONA, Israel – February 1, 2017 — Kamada Ltd. (NASDAQ and TASE: KMDA), a
plasma-derived protein therapeutics company focused on orphan indications, announced
today that it will release financial results for the fiscal year ended December 31, 2016 prior
to the open of the U.S. financial markets on Monday, February 6, 2017.
Kamada management will host an investment community conference call on Monday,
February 6 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing
888-452-4034 (from within the U.S.), 1 80 924 5905 (from Israel), or 719-457-2087
(International) and entering the conference identification number: 5468241. The call will
also be webcast live on the internet on the Company's website at
A replay of the call will be accessible two hours after its completion through February 20
by dialing 844-512-2921 (from within the U.S.) or 412-317-6671 (from outside the U.S.)
and entering the conference identification number: 5468241. The call will also be archived
for 90 days on the Company's website at

About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and
has a commercial product portfolio and a robust late-stage product pipeline. The Company
uses its proprietary platform technology and know-how for the extraction and purification
of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified,
liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived
from human plasma with known and newly-discovered therapeutic roles given its
immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties.
The Company's flagship product is GLASSIA®, the first and only liquid, ready-to-use,
intravenous plasma-derived AAT product approved by the U.S. Food and Drug
Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership
with Baxalta (now part of Shire plc) and in other counties through local distributors. In
addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products
administered by injection or infusion, that are marketed through distributors in more than
15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and
Asia. Kamada has five late-stage plasma-derived protein products in development,
including an inhaled formulation of AAT for the treatment of AAT deficiency for which a
MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in
Europe. Kamada has also completed its Phase 2 clinical trials in the U.S for the treatment of
AAT deficiency with inhaled AAT. In addition, Kamada's intravenous AAT is in development
for other indications such as type-1 diabetes, GvHD and prevention of lung transplant
rejection. Kamada also leverages its expertise and presence in the plasma-derived protein
therapeutics market by distributing more than 10 complementary products in Israel that
are manufactured by third parties.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the
U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of
1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that are not historical
facts, such as statements regarding assumptions and results related to financial results
forecast, commercial results, timing and results of clinical trials and EMA and U.S. FD
submissions and authorizations. Forward-looking statements are based on Kamada's
current knowledge and its present beliefs and expectations regarding possible future
events and are subject to risks, uncertainties and assumptions. Actual results and the
timing of events could differ materially from those anticipated in these forward-looking
statements as a result of several factors including, but not limited to, unexpected results of
clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional
competition in the AATD market or further regulatory delays. The forward-looking
statements made herein speak only as of the date of this announcement and Kamada
undertakes no obligation to update publicly such forward-looking statements to reflect
subsequent events or circumstances, except as otherwise required by law.

Gil Efron
Deputy CEO & Chief Financial Officer

Bob Yedid
LifeSci Advisors, LLC